儿童拔管失败与非侵入性呼吸支持使用的当代趋势
该回顾性横断面研究基于北美158个中心的质量改进数据库,纳入2013至2022年间接受有创机械通气≥24小时且拔管的19岁以下患儿132712例次。总体拔管失败率为8.5%。拔管后非侵入性呼吸支持使用从2013年的20.9%增至2022年的39.9%(RR 1.90,95%CI 1.83-1.98,P<.01),而拔管失败率轻度下降(≤48小时:8.9% vs 8.1%,RR 0.92,95%CI 0.85-0.99,P=.03;≤7天:12.3% vs 11.0%,RR 0.89,95%CI 0.83-0.95,P<.01)。拔管失败与较长机械通气时间、PICU住院时间和住院时间相关,但与风险校正后的全因死亡率无关。
要点
- 2013至2022年间,拔管后非侵入性呼吸支持使用从20.9%增至39.9%(RR 1.90,95%CI 1.83-1.98,P<.01),拔管失败率≤48小时从8.9%降至8.1%(RR 0.92,95%CI 0.85-0.99,P=.03)。
- 拔管失败风险增加与年龄<6周(OR 1.39,95%CI 1.31-1.47)、6周至12个月(OR 1.24,95%CI 1.18-1.30)、肾脏诊断(OR 1.25,95%CI 1.04-1.48)、呼吸诊断(OR 1.15,95%CI 1.07-1.23)、心脏诊断(OR 1.10,95%CI 1.04-1.16)及拔管前有创通气≥7天(OR 1.26,95%CI 1.21-1.32)相关
- 对于有0或1个危险因素的患者,拔管失败率随时间无变化。
- 拔管失败与较长机械通气时间(11.6天 vs 4.0天,P<.01)、较长PICU住院时间(18.8天 vs 7.9天,P<.01)和较长住院时间(31.0天 vs 15.0天,P<.01)相关,但与风险校正后的全因死亡率无关(8.5% vs 8.6%,RR 1.16,95%CI 0.97-1.38,P=.73)。
适用人群与场景
- 2013至2022年间来自158个北美中心的19岁以下患者,接受有创机械通气≥24小时并拔管。
研究设计与关键结果
- 回顾性横断面研究,纳入132712例次独特 encounter,来自158个北美中心的质量改进数据库。
- 总体拔管失败率为8.5%。
- 拔管后非侵入性呼吸支持使用从2013年20.9%增至2022年39.9%(RR 1.90,95%CI 1.83-1.98,P<.01)。
- 拔管失败率≤48小时从2013年8.9%降至2022年8.1%(RR 0.92,95%CI 0.85-0.99,P=.03);≤7天从12.3%降至11.0%(RR 0.89,95%CI 0.83-0.95,P<.01)。
- 逻辑回归显示拔管失败 odds 增加与年龄<6周(OR 1.39,95%CI 1.31-1.47)、6周至12个月(OR 1.24,95%CI 1.18-1.30)、主要肾脏诊断(OR 1.25,95%CI 1.04-1.48)、呼吸诊断(OR 1.15,95%CI 1.07-1.23)、心脏诊断(OR 1.10,95%CI 1.04-1.16)及拔管前有创通气≥7天(OR 1.26,95%CI 1.21-1.32)相关。
- 有0或1个危险因素的患者拔管失败率随时间无变化。
- 拔管失败与较长机械通气时间(11.6天 vs 4.0天,P<.01)、较长PICU住院时间(18.8天 vs 7.9天,P<.01)和较长住院时间(31.0天 vs 15.0天,P<.01)相关,但与风险校正后的全因死亡率无关(8.5% vs 8.6%,RR 1.16,95%CI 0.97-1.38,P=.73)。
证据类型、等级与局限
- 证据类型:回顾性横断面研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,高危组可能受益于拔管后非侵入性呼吸支持,但低危组可能存在过度使用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Prolonged invasive mechanical ventilation (IMV) is associated with morbidity and mortality in children. Timely extubation is essential and must balance the competing risks of extubation failure (EF) and prolonged use of noninvasive respiratory support after extubation.
RESEARCH QUESTION: Did EF risk factors, EF rates, noninvasive respiratory support after extubation practices, and patient-centered outcomes changed between 2013 and 2022?
STUDY DESIGN AND METHODS: Retrospective cross-sectional study of patients younger than 19 years receiving IMV for ≥ 24 hours and extubated between 2013 and 2022 from 158 North American sites in the Virtual Pediatric Intensive Care, LLC, quality improvement database.
RESULTS: One hundred thirty-two thousand seven hundred twelve unique encounters were included. The overall EF rate was 8.5%. Postextubation noninvasive respiratory support use nearly doubled (2013 vs 2022: 20.9% vs 39.9%; relative risk [RR], 1.90 [95% CI, 1.83-1.98]; P < .01), whereas EF decreased slightly (≤ 48 hours: 8.9% vs 8.1%; RR, 0.92 [95% CI, 0.85-0.99]; P = .03; ≤ 7 days: 12.3% vs 11.0%; RR, 0.89 [95% CI, 0.83-0.95]; P < .01). Logistic regression identified increased odds of EF associated with younger age (< 6 weeks: OR, 1.39 [95% CI, 1.31-1.47]; P < .01; 6 weeks-12 months: OR, 1.24 [95% CI, 1.18-1.30]; P < .01), primary renal diagnosis (OR, 1.25 [95% CI, 1.04-1.48]; P = .01), respiratory diagnosis (OR, 1.15 [95% CI, 1.07-1.23]; P < .01), and cardiac diagnosis (OR, 1.10 [95% CI, 1.04-1.16]; P < .01), and ≥ 7 days of invasive ventilation before extubation (OR, 1.26 [95% CI, 1.21-1.32]; P < .01). EF rates were unchanged over time for patients with 0 or 1 risk factor. EF was associated with longer mechanical ventilation duration (11.6 days vs 4.0 days; P < .01), longer pediatric ICU length of stay (18.8 days vs 7.9 days; P < .01), and longer hospital length of stay (31.0 days vs 15.0 days; P < .01), but not with all-cause risk-adjusted mortality (8.5% vs 8.6%; RR, 1.16 [95% CI, 0.97-1.38]; P = .73).
INTERPRETATION: Our results demonstrate that in the last decade, noninvasive respiratory support after extubation has nearly doubled, with an approximately 10% reintubation risk reduction. High-risk groups may benefit, but overuse may exist in low-risk groups with respect to EF. EF is associated with morbidity, but not increased mortality.
参考来源
- Loberger JM, Moore M, Scanlon M, et al. Contemporary Trends in Pediatric Extubation Failure and Noninvasive Respiratory Support Use. Chest. 2025. PMID: 40818775. doi:10.1016/j.chest.2025.07.4080
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。